

Tissue	Dose (mg/kg)	AUC ($\mu\text{g}\cdot\text{h/L}$)	C_{max} ($\mu\text{mol/L}$)	$T_{1/2}$ (h)
Serum	100	119	241	0.243
Brain	100	139	60	0.967
Liver	100	1150	1695	/
Kidney	100	24.5	23.6	0.308

Pharmacokinetic analysis of mouse serum and tissue at a dose of 300mg/kg^[1]

300mg/kg^[1]

Tissue	Dose (mg/kg)	AUC ($\mu\text{g}\cdot\text{h/L}$)	C_{max} ($\mu\text{mol/L}$)	$T_{1/2}$ (h)
Serum	300	436	374	0.468
Brain	300	313	141	0.883
Liver	300	/	/	/
Kidney	300	/	/	/

Pharmacokinetic analysis of mouse serum and tissue at a dose of 500mg/kg^[1]

500mg/kg^[1]

Tissue	Dose (mg/kg)	AUC ($\mu\text{g}\cdot\text{h/L}$)	C_{max} ($\mu\text{mol/L}$)	$T_{1/2}$ (h)
Serum	500	717	451	0.683
Brain	500	1280	530	0.761
Liver	500	/	/	/
Kidney	500	/	/	/

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	GBL induced mouse model ^[1]
Dosage:	300 mg/kg(Combined with diclofenac (25 mg/kg))
Administration:	Intraperitoneal injection (i.p.), Thirty minutes later, mice were given an i.p. injection of GBL (100 mg/kg diluted in PBS)
Result:	In the presence of diclofenac, it was highly protective against GBL mediated responses.

Animal Model:	GBL induced mouse model ^[3]
Dosage:	0.83, 1.25, 1.66, 2.08mmol/kg
Administration:	Intraperitoneal injection (i.p.), 30 min before the test
Result:	At a dosage of 2.08 mmol/kg, completely blocked the effect of GHB when administered at 3.18 mmol/kg

REFERENCES

- [1]. Ainslie GR, et al. A pharmacokinetic evaluation and metabolite identification of the GHB receptor antagonist NCS-382 in mouse informs novel therapeutic strategies for the treatment of GHB intoxication. *Pharmacol Res Perspect*. 2016 Oct 18;4(6):e00265.
- [2]. Vogel KR, et al. In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of γ -hydroxybutyrate (GHB) binding. *Toxicol In Vitro*. 2017 Apr;40:196-202
- [3]. Schmidt C, et al. Anti-sedative and anti-cataleptic properties of NCS-382, a gamma-hydroxybutyrate receptor antagonist. *Eur J Pharmacol*. 1991 Oct 22;203(3):393-7.
- [4]. Maitre M, Hechler V, Vayer P, Gobaille S, Cash CD, Schmitt M, Bourguignon JJ. A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. *J Pharmacol Exp Ther*. 1990 Nov;255(2):657-63.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA